TY - JOUR A1 - Hofmann, Sigrun Ruth A1 - Böttger, Fanny A1 - Range, Ursula A1 - Lück, Christian A1 - Morbach, Henner A1 - Girschick, Hermann Joseph A1 - Suttorp, Meinolf A1 - Hedrich, Christian Michael T1 - Serum interleukin-6 and CCL11/eotaxin may be suitable biomarkers for the diagnosis of chronic nonbacterial osteomyelitis JF - Frontiers in Pediatrics N2 - Objectives: Chronic recurrent multifocal osteomyelitis (CRMO), the most severe form of chronic nonbacterial osteomyelitis (CNO), is an autoinflammatory bone disorder. In the absence of diagnostic criteria or biomarkers, CNO/CRMO remains a diagnosis of exclusion. The aim of this study was to identify biomarkers for diagnosing multifocal disease (CRMO). Study design: Sera from 71 pediatric CRMO patients, 11 patients with osteoarticular infections, 62 patients with juvenile idiopathic arthritis (JIA), 7 patients with para-infectious or reactive arthritis, and 43 patients with acute leukemia or lymphoma, as well as 59 healthy individuals were collected. Multiplex analysis of 18 inflammation- and/or bone remodeling-associated serum proteins was performed. Statistical analysis included univariate ANOVA, discriminant analysis, univariate receiver operating characteristic (ROC) analysis, and logistic regression analyses. Results: For 14 of 18 blood serum proteins, significant differences were determined between CRMO patients, at least one alternative diagnosis, or healthy controls. Multi-component discriminant analysis delivered five biomarkers (IL-6, CCL11/eotaxin, CCL5/RANTES, collagen Iα, sIL-2R) for the diagnosis of CRMO. ROC analysis allowed further reduction to a core set of 2 biomarkers (CCL11/eotaxin, IL-6) that are sufficient to discern between CRMO, healthy controls, and alternative diagnoses. Conclusion: Serum biomarkers CCL11/eotaxin and IL-6 differentiate between patients with CRMO, healthy controls, and alternative diagnoses (leukemia and lymphoma, osteoarticular infections, para-infectious arthritis, and JIA). Easily accessible biomarkers may aid in diagnosing CRMO. Further studies testing biomarkers in larger unrelated cohorts are warranted. KW - medicine KW - chronic nonbacterial osteomyelitis KW - chronic recurrent multifocal osteomyelitis KW - inflammation KW - biomarker KW - autoinflammation KW - diagnosis Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-172744 VL - 5 ER - TY - JOUR A1 - Harter, Philipp A1 - Hauke, Jan A1 - Heitz, Florian A1 - Reuss, Alexander A1 - Kommoss, Stefan A1 - Marmé, Frederik A1 - Heimbach, André A1 - Prieske, Katharina A1 - Richters, Lisa A1 - Burges, Alexander A1 - Neidhardt, Guido A1 - de Gregorio, Nikolaus A1 - El-Balat, Ahmed A1 - Hilpert, Felix A1 - Meier, Werner A1 - Kimmig, Rainer A1 - Kast, Karin A1 - Sehouli, Jalid A1 - Baumann, Klaus A1 - Jackisch, Christian A1 - Park-Simon, Tjoung-Won A1 - Hanker, Lars A1 - Kröber, Sandra A1 - Pfisterer, Jacobus A1 - Gevensleben, Heidrun A1 - Schnelzer, Andreas A1 - Dietrich, Dimo A1 - Neunhöffer, Tanja A1 - Krockenberger, Mathias A1 - Brucker, Sara Y. A1 - Nürnberg, Peter A1 - Thiele, Holger A1 - Altmüller, Janine A1 - Lamla, Josefin A1 - Elser, Gabriele A1 - du Bois, Andreas A1 - Hahnen, Eric A1 - Schmutzler, Rita T1 - Prevalence of deleterious germline variants in risk genes including \(BRCA1/2\) in consecutive ovarian cancer patients (AGO-TR-1) JF - PLoS ONE N2 - Background Identification of families at risk for ovarian cancer offers the opportunity to consider prophylactic surgery thus reducing ovarian cancer mortality. So far, identification of potentially affected families in Germany was solely performed via family history and numbers of affected family members with breast or ovarian cancer. However, neither the prevalence of deleterious variants in \(BRCA1/2\) in ovarian cancer in Germany nor the reliability of family history as trigger for genetic counselling has ever been evaluated. Methods Prospective counseling and germline testing of consecutive patients with primary diagnosis or with platinum-sensitive relapse of an invasive epithelial ovarian cancer. Testing included 25 candidate and established risk genes. Among these 25 genes, 16 genes (\(ATM\), \(BRCA1\), \(BRCA2\), \(CDH1\), \(CHEK2\), \(MLH1\), \(MSH2\), \(MSH6\), \(NBN\), \(PMS2\), \(PTEN\), \(PALB2\), \(RAD51C\), \(RAD51D\), \(STK11\), \(TP53\)) were defined as established cancer risk genes. A positive family history was defined as at least one relative with breast cancer or ovarian cancer or breast cancer in personal history. Results In total, we analyzed 523 patients: 281 patients with primary diagnosis of ovarian cancer and 242 patients with relapsed disease. Median age at primary diagnosis was 58 years (range 16–93) and 406 patients (77.6%) had a high-grade serous ovarian cancer. In total, 27.9% of the patients showed at least one deleterious variant in all 25 investigated genes and 26.4% in the defined 16 risk genes. Deleterious variants were most prevalent in the \(BRCA1\) (15.5%), \(BRCA2\) (5.5%), \(RAD51C\) (2.5%) and \(PALB2\) (1.1%) genes. The prevalence of deleterious variants did not differ significantly between patients at primary diagnosis and relapse. The prevalence of deleterious variants in \(BRCA1/2\) (and in all 16 risk genes) in patients <60 years was 30.2% (33.2%) versus 10.6% (18.9%) in patients \(\geq\)60 years. Family history was positive in 43% of all patients. Patients with a positive family history had a prevalence of deleterious variants of 31.6% (36.0%) versus 11.4% (17.6%) and histologic subtype of high grade serous ovarian cancer versus other showed a prevalence of deleterious variants of 23.2% (29.1%) and 10.2% (14.8%), respectively. Testing only for \(BRCA1/2\) would miss in our series more than 5% of the patients with a deleterious variant in established risk genes. Conclusions 26.4% of all patients harbor at least one deleterious variant in established risk genes. The threshold of 10% mutation rate which is accepted for reimbursement by health care providers in Germany was observed in all subgroups analyzed and neither age at primary diagnosis nor histo-type or family history sufficiently enough could identify a subgroup not eligible for genetic counselling and testing. Genetic testing should therefore be offered to every patient with invasive epithelial ovarian cancer and limiting testing to \(BRCA1/2\) seems to be not sufficient. KW - medicine KW - Genetic causes of cancer KW - ovarian cancer KW - cancer risk factors KW - histology KW - cancer detection and diagnosis KW - breast cancer KW - genetic testing KW - human genetics Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-173553 VL - 12 IS - 10 ER - TY - JOUR A1 - Rueegg, Corina S. A1 - Kriemler, Susi A1 - Zuercher, Simeon J. A1 - Schindera, Christina A1 - Renner, Andrea A1 - Hebestreit, Helge A1 - Meier, Christian A1 - Eser, Prisca A1 - von der Weid, Nicolas X. T1 - A partially supervised physical activity program for adult and adolescent survivors of childhood cancer (SURfit): study design of a randomized controlled trial [NCT02730767] JF - BMC Cancer N2 - Background: Beyond survival of nowadays >80%, modern childhood cancer treatment strives to preserve long-term health and quality of life. However, the majority of today’s survivors suffer from short- and long-term adverse effects such as cardiovascular and pulmonary diseases, obesity, osteoporosis, fatigue, depression, and reduced physical fitness and quality of life. Regular exercise can play a major role to mitigate or prevent such late-effects. Despite this, there are no data on the effects of regular exercise in childhood cancer survivors from randomized controlled trials (RCTs). \(Primary\) \(outcome\) of the current RCT is therefore the effect of a 12-months exercise program on a composite cardiovascular disease risk score in childhood cancer survivors. \(Secondary\) \(outcomes\) are single cardiovascular disease risk factors, glycaemic control, bone health, body composition, physical fitness, physical activity, quality of life, mental health, fatigue and adverse events (safety). Methods: A total of 150 childhood cancer survivors aged ≥16 years and diagnosed ≥5 years prior to the study are recruited from Swiss paediatric oncology clinics. Following the baseline assessments patients are randomized 1:1 into an intervention and control group. Thereafter, they are seen at month 3, 6 and 12 for follow-up assessments. The intervention group is asked to add ≥2.5 h of intense physical activity/week, including 30 min of strength building and 2 h of aerobic exercises. In addition, they are told to reduce screen time by 25%. Regular consulting by physiotherapists, individual web-based activity diaries, and pedometer devices are used as motivational tools for the intervention group. The control group is asked to keep their physical activity levels constant. Discussion: The results of this study will show whether a partially supervised exercise intervention can improve cardiovascular disease risk factors, bone health, body composition, physical activity and fitness, fatigue, mental health and quality of life in childhood cancer survivors. If the program will be effective, all relevant information of the SURfit physical activity intervention will be made available to interested clinics that treat and follow-up childhood cancer patients to promote exercise in their patients. KW - Medicine KW - Randomized controlled trial KW - Physical activity KW - Exercise intervention KW - Childhood cancer survivors KW - Late-effects KW - Cardiovascular disease KW - Bone health KW - Body composition KW - Physical fitness KW - Quality of life Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-172497 VL - 17 ER - TY - JOUR A1 - Bekes, Inga A1 - Friedl, Thomas W. P. A1 - Köhler, Tanja A1 - Möbus, Volker A1 - Janni, Wolfgang A1 - Wöckel, Achim A1 - Wulff, Christine T1 - Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer? JF - Molecular Cancer N2 - Background Ovarian cancer is mostly associated with pathologically regulated permeability of peritoneal vessels, leading to ascites. Here, we investigated the molecular regulation of endothelial permeability by the vascular endothelial growth factor (VEGF) and both tight and adherens junction proteins (VE-cadherin and claudin 5) with regards to the tumor biology of different ovarian cancer types. Methods Serum and ascites samples before and after surgery, as well as peritoneal biopsies of 68 ovarian cancer patients and 20 healthy controls were collected. In serum and ascites VEGF protein was measured by ELISA. In peritoneal biopsies co-localization of VE-cadherin and claudin 5 was investigated using immunohistochemical dual staining. In addition, the gene expression of VE-cadherin and claudin 5 was quantified by Real-time PCR. Differences in VEGF levels, VE-cadherin and claudin 5 gene expression were analyzed in relation to various tumor characteristics (tumor stage, grading, histological subtypes, resection status after surgery) and then compared to controls. Furthermore, human primary ovarian cancer cells were co-cultured with human umbilical vein endothelial cells (HUVEC) and changes in VE-cadherin and claudin 5 were investigated after VEGF inhibition. Results VEGF was significantly increased in tumor patients in comparison to controls and accumulates in ascites. The highest VEGF levels were found in patients diagnosed with advanced tumor stages, with tumors of poor differentiation, or in the group of solid / cystic-solid tumors. Patients with residual tumor after operation showed significantly higher levels of VEGF both before and after surgery as compared to tumor-free resected patients. Results of an immunohistochemical double-staining experiment indicated co-localization of VE-cadherin and claudin 5 in the peritoneal vasculature. Compared to controls, expression of VE-cadherin and claudin 5 was significantly suppressed in peritoneal vessels of tumor patients, but there were no significant differences regarding VE-cadherin and claudin 5 expression in relation to different tumor characteristics. A significant positive correlation was found between VE-cadherin and claudin 5 expression. VEGF inhibition in vitro was associated with significant increase in VE-cadherin and claudin 5. Conclusions Our results indicate that increased peritoneal permeability in ovarian cancer is due to down-regulation of adhesion proteins via tumor derived VEGF. Advanced ovarian cancer with aggressive tumor biology may be associated with early dysregulation of vascular permeability leading to ascites. These patients may benefit from therapeutic VEGF inhibition. KW - ovarian cancer KW - vascular permeability KW - ascites KW - VEGF KW - claudin 5 KW - VE-cadherin Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-169298 VL - 15 IS - 13 ER - TY - JOUR A1 - Joukhadar, R. A1 - Wöckel, A. A1 - Herr, D. A1 - Paulus, V. A1 - Radosa, J. A1 - Hamza, A. A1 - Solomayer, E. A1 - Baum, S. T1 - Challenges of Longevity: Safety of Vaginal and Laparoscopic Urogynecological Procedures in Septuagenarians and Older Patients JF - BioMed Research International N2 - Introduction. Pelvic organ prolapse (POP) and urinary incontinence (UI) have increasing prevalence in the elderly population. The aim of this study was to compare the comorbidities of these procedures between <70 y/o and ≥70 y/o patients. Materials and Methods. In our retrospective study over a period of 2.5 years, 407 patients had received an urogynecological procedure. All patients with POP were treated by reconstructive surgery. Complications were reported using the standardized classification of Clavien-Dindo (CD). The study can be assigned to stage 2b Exploration IDEAL (Idea, Development, Exploration, Assessment, Long-term study)-system of surgical innovation. Results. Operation time, blood loss, and intraoperative complications have not been more frequent in the elderly, whereas hospital stay was significantly longer in ≥70 y/o patients. Regarding postoperative complications, we noticed that ≥70 y/o patients had an almost threefold risk to develop mild early postoperative complications compared to younger patients (OR: 2.86; 95% CI: 1.76–4.66). On the contrary, major complications were not more frequent. No case of life-threatening complication or the need for blood transfusion was reported. Conclusion. After urogynecological procedures, septuagenarians and older patients are more likely to develop mild postoperative complications but not more intraoperative or severe postoperative complications compared to younger patients. KW - gynecologic surgical procedures/methods KW - postoperative complications/epidemiology KW - vagina/surgery KW - pelvic organ prolapse/surgery KW - middle Aged KW - laparoscopy/methods KW - uterine prolapse/surgery KW - urinary incontinence/surgery KW - surgical Mesh KW - retrospective Studies KW - age factors KW - aged KW - aged 80 and over KW - female KW - reconstructive surgical procedures/methods Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-161005 VL - 2016 IS - Article ID 5184595 ER - TY - JOUR A1 - Biehl, Stefanie C. A1 - Merz, Christian J. A1 - Dresler, Thomas A1 - Heupel, Julia A1 - Reichert, Susanne A1 - Jacob, Christian P. A1 - Deckert, Jürgen A1 - Herrmann, Martin J. T1 - Increase or Decrease of fMRI Activity in Adult Attention Deficit/ Hyperactivity Disorder: Does It Depend on Task Difficulty? JF - International Journal of Neuropsychopharmacology N2 - Background: Attention deficit/hyperactivity disorder has been shown to affect working memory, and fMRI studies in children and adolescents with attention deficit/hyperactivity disorder report hypoactivation in task-related attentional networks. However, studies with adult attention deficit/hyperactivity disorder patients addressing this issue as well as the effects of clinically valid methylphenidate treatment are scarce. This study contributes to closing this gap. Methods: Thirty-five adult patients were randomized to 6 weeks of double-blind placebo or methylphenidate treatment. Patients completed an fMRI n-back working memory task both before and after the assigned treatment, and matched healthy controls were tested and compared to the untreated patients. Results: There were no whole-brain differences between any of the groups. However, when specified regions of interest were investigated, the patient group showed enhanced BOLD responses in dorsal and ventral areas before treatment. This increase was correlated with performance across all participants and with attention deficit/hyperactivity disorder symptoms in the patient group. Furthermore, we found an effect of treatment in the right superior frontal gyrus, with methylphenidate-treated patients exhibiting increased activation, which was absent in the placebo-treated patients. Conclusions: Our results indicate distinct activation differences between untreated adult attention deficit/hyperactivity disorder patients and matched healthy controls during a working memory task. These differences might reflect compensatory efforts by the patients, who are performing at the same level as the healthy controls. We furthermore found a positive effect of methylphenidate on the activation of a frontal region of interest. These observations contribute to a more thorough understanding of adult attention deficit/hyperactivity disorder and provide impulses for the evaluation of therapy-related changes. KW - working memory KW - clinical trial KW - child memory KW - short-term methylphenidate brain KW - methylphenidate KW - adult attention deficit/hyperactivity disorder KW - fMRI KW - functional magnetic resonance imaging Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-147551 VL - 19 IS - 10 ER - TY - JOUR A1 - Dietl, Sebastian A1 - Schwinn, Stefanie A1 - Dietl, Susanne A1 - Riedl, Simone A1 - Deinlein, Frank A1 - Rutkowski, Stefan A1 - von Bueren, Andre O. A1 - Krauss, Jürgen A1 - Schweitzer, Tilmann A1 - Vince, Giles H. A1 - Picard, Daniel A1 - Eyrich, Matthias A1 - Rosenwald, Andreas A1 - Ramaswamy, Vijay A1 - Taylor, Michael D. A1 - Remke, Marc A1 - Monoranu, Camelia M. A1 - Beilhack, Andreas A1 - Schlegel, Paul G. A1 - Wölfl, Matthias T1 - MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties JF - BMC Cancer N2 - Background Medulloblastoma is the most common malignant brain tumor in children and can be divided in different molecular subgroups. Patients whose tumor is classified as a Group 3 tumor have a dismal prognosis. However only very few tumor models are available for this subgroup. Methods We established a robust orthotopic xenograft model with a cell line derived from the malignant pleural effusions of a child suffering from a Group 3 medulloblastoma. Results Besides classical characteristics of this tumor subgroup, the cells display cancer stem cell characteristics including neurosphere formation, multilineage differentiation, CD133/CD15 expression, high ALDH-activity and high tumorigenicity in immunocompromised mice with xenografts exactly recapitulating the original tumor architecture. Conclusions This model using unmanipulated, human medulloblastoma cells will enable translational research, specifically focused on Group 3 medulloblastoma. KW - cancer stem cells KW - anaplastic medulloblastoma KW - group 3 KW - orthotopic xenograft KW - animal model KW - brain tumor KW - children Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-145877 VL - 16 IS - 115 ER - TY - JOUR A1 - Montalbán del Barrio, Itsaso A1 - Penski, Cornelia A1 - Schlahsa, Laura A1 - Stein, Roland G. A1 - Diessner, Joachim A1 - Wöckel, Achim A1 - Dietl, Johannes A1 - Lutz, Manfred B. A1 - Mittelbronn, Michel A1 - Wischhusen, Jörg A1 - Häusler, Sebastian F. M. T1 - Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape JF - Journal for ImmunoTherapy of Cancer N2 - Background Ovarian cancer (OvCA) tissues show abundant expression of the ectonucleotidases CD39 and CD73 which generate immunomodulatory adenosine, thereby inhibiting cytotoxic lymphocytes. Little, however, is known about the effect of adenosine on myeloid cells. Considering that tumor associated macrophages (TAM) and myeloid-derived suppressor cells (MDSC) constitute up to 20 % of OvCA tissue, we investigated the effect of adenosine on myeloid cells and explored a possible contribution of myeloid cells to adenosine generation in vitro and ex vivo. Methods Monocytes were used as human blood-derived myeloid cells. After co-incubation with SK-OV-3 or OAW-42 OvCA cells, monocyte migration was determined in transwell assays. For conversion into M2-polarized “TAM-like” macrophages, monocytes were co-incubated with OAW-42 cells. Ex vivo TAMs were obtained from OvCA ascites. Macrophage phenotypes were investigated by intracellular staining for IL-10 and IL-12. CD39 and CD73 expression were assessed by FACS analysis both on in vitro-induced TAM-like macrophages and on ascites-derived ex situ-TAMs. Myeloid cells in solid tumor tissue were analyzed by immunohistochemistry. Generation of biologically active adenosine by TAM-like macrophages was measured in luciferase-based reporter assays. Functional effects of adenosine were investigated in proliferation-experiments with CD4+ T cells and specific inhibitors. Results When CD39 or CD73 activity on OvCA cells were blocked, the migration of monocytes towards OvCA cells was significantly decreased. In vivo, myeloid cells in solid ovarian cancer tissue were found to express CD39 whereas CD73 was mainly detected on stromal fibroblasts. Ex situ-TAMs and in vitro differentiated TAM-like cells, however, upregulated the expression of CD39 and CD73 compared to monocytes or M1 macrophages. Expression of ectonucleotidases also translated into increased levels of biologically active adenosine. Accordingly, co-incubation with these TAMs suppressed CD4+ T cell proliferation which could be rescued via blockade of CD39 or CD73. Conclusion Adenosine generated by OvCA cells likely contributes to the recruitment of TAMs which further amplify adenosine-dependent immunosuppression via additional ectonucleotidase activity. In solid ovarian cancer tissue, TAMs express CD39 while CD73 is found on stromal fibroblasts. Accordingly, small molecule inhibitors of CD39 or CD73 could improve immune responses in ovarian cancer. KW - ovarian cancer KW - adenosine KW - CD39 KW - tumor associated macrophages KW - immune escape KW - CD73 Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-146624 VL - 4 IS - 49 ER - TY - THES A1 - Taschik, Julia T1 - Zytokingenpolymorphismen bei Kindern mit akuter lymphatischer Leukämie T1 - Genetic cytokine polymorphism in children with acute lymphoblastic leukamie N2 - Die akute lymphatische Leukämie ist die häufigste maligne Erkrankung im Kindesalter. Trotz systematischer Erhebung und Auswertung von Daten im Rahmen der ALL-BFM-Studiengruppe und der damit verbundenen kontinuierlichen Verbesserung der Prognose hat man noch immer keine Ursache für eine ALL gefunden. Daher nimmt eine umfangreiche Risikostratifizierung eine zentrale Rolle in der Behandlungsplanung einer ALL ein. Basierend auf einer exakten Stratifizierung kann die Therapie risikoadaptiert und individualisiert werden, um eine Übertherapie zu vermeiden und letztlich die Heilungschancen zu verbessern. Pro- und antiinflammatorische Zytokine kommt in den komplexen Wirkungsmechanismen des Immunsystems eine Schlüsselrolle zu. Viele Infektions-, Auto-immun- oder Tumorerkrankungen werden durch das Produktionsprofil der Zyto-kine beeinflusst. Da genetisch determinierte Zytokingenpolymorphismen Krank-heitsverläufe beeinflussen und verändern, wurde untersucht, ob Zytokine einen Einfluss auf pädiatrische Patienten mit einer ALL haben. Im Zuge dieser Arbeit wurden 95 pädiatrische Patienten mit ALL auf Polymorphismen der Zytokine TNF-α, TGF-β1, IL-10, IL-6 und IFN-γ analysiert, die im Zeitraum vom 21.06.2004 bis zum 30.04.2014 an der Kinderklinik des Universitätsklinikums Würzburg behandelt wurden. Mittels DNA-Extraktion, sequenz-spezifischer PCR und Gelelektropherese wurden 35 Proben bei Erstdiagnose und 93 zum Zeitpunkt der Remission mit folgender zentralen Fragestellung untersucht: Gibt es genetische Risikofaktoren, die Einfluss auf • die Risikogruppe • die Art der Leukämie • die Genfrequenz • die Rezidivrate und • das Gesamtüberleben einer akuten lymphatische Leukämie im Kindesalter haben und sich zudem durch Einzelnukleotidpolymorphismen in pro- und antiinflammatorischen Zytokinen auszeichnen? Im Rahmen dieser Studie konnte festgestellt werden, dass das immunsuppressive Zytokin IL-10 einen Einfluss auf die Genfrequenz, die Risikogruppe, die Rezidivrate sowie die Prognose bei Kindern mit ALL hat. Patienten mit niedrigen Zytokinexpressionsraten (Genotypen ACC/ACC und ACC/ATA) wurden häufiger in der Hochrisikogruppe therapiert, hatten mehr Rezidive und eine schlechtere Prognose als Patienten mit hohen Zytokinexpressionsraten. Dar-über hinaus ist der Genotyp GCC/ACC signifikant häufiger bei ALL-Patienten anzutreffen als im gesunden Kollektiv. Beim immunsuppressiven IL-6 konnte festgestellt werden, dass der Genotyp C/C signifikant häufiger bei Patienten mit einer ALL auftritt als bei gesunden Patienten. Ferner zeigte sich, dass es so-wohl für IL-6 als auch für TNF-α eine Änderung des Genotyps zwischen Erstdiagnose und in Remission auftrat, die Hinweise auf einen blastenspezifischen „immune-escape“-Mechanismus geben. Ebenfalls konnte gezeigt werden, dass das immunmodulatorische Zytokin TGF-β1 einen Einfluss auf die Risikogruppe sowie die Rezidivrate hat. Patienten, die eine T/T Kombination am Codon 10 aufwiesen wurden häufiger im Hochrisikozweig therapiert als Patienten mit den Genotypen T/C oder C/C. Des Weiteren wurde demonstriert, dass Patienten mit einem C/C an Codon 25 häufiger an Rezidiven erkrankten als Patienten mit ei-nem G/C oder G/G. Für die TH1 Zytokine IFN-γ sowie TNF-α wurde kein Zusammenhang zwischen der Genfrequenz, der Risikogruppe, der Art der Leukämie, der Rezidivrate oder dem Gesamtüberleben gefunden. Auch wenn man bisher noch nicht genau weiß, wie Zytokingenpolymorphismen Einfluss auf pädiatrische ALL nehmen, wird anhand dieser Arbeit gezeigt, dass Zytokine einen Beitrag zur Pathogenese der ALL leisten und daher zukünftig für eine umfassendere Risikostratifizierung geeignet sind. Darüber hinaus können diese Ergebnisse dazu beitragen, dass Zytokine als biologische Marker etabliert werden, um eine weniger toxische immunmodulierende bzw. -suppressive Therapie zu gewährleisten. Dies führt dazu, dass eine Therapie anhand des Risikoprofils individuell und prognoseverbessernd abgestimmt werden kann. Je-doch wäre für eine nachfolgende Untersuchung eine größere multizentrische Stichprobe sowie eine prospektive Evaluation der Daten erstrebenswert. Gera-de bei hereditären Erkrankungen haben einzelne Gene nur einen geringen Einfluss auf das Gesamtrisiko, sodass größere Fallzahlen erforderlich wären, um auch schwache Effekte zu detektieren. N2 - Acute lymphoblastic leukaemia (ALL) is the most common malignant disease in childhood. Although survival rates in paediatric patients with ALL have greatly improved since effective drug combinations and risk-adapted therapy protocols were introduced, possible causes for ALL are yet to be determined. The incomplete information on the pathogenesis of ALL heightens the need for extensive risk stratification in order to develop and improve treatment methods. Exact stratification helps to continuously improve and develop risk-adapted and individual therapy approaches to minimise over- or under-treatment. Based on the empirical finding that cytokines play a decisive role in immune responses and that many autoimmune and malignant diseases are influenced by cytokine production, this study hypothesized that genetically determined cy-tokine gene polymorphisms might have an impact on children with ALL. 95 pediatric ALL patients were examined between June 2004 and April 2013 at the Children’s Hospital of the University of Würzburg with regard to cytokine gene polymorphisms in TNF-α, TGF-β1, IL-10, IL-6 and IFN-γ. Applying DNA extraction, sequence-specific PCR and gel electrophoresis, 35 samples at initial diagnosis and 93 samples in remission were obtained in order to find an answer to the following question: Are there any genetic risk factors, which influence the • risk group • type of leukaemia • gene frequency • relapse rate • overall survival with acute lymphoblastic leukaemia in childhood? Within the scope of this study the immunosuppressive IL-10 has an influence on gene frequency, risk group, relapse rate and overall survival. IL-10 high-producer-haplotypes were reduced in ALL-patients compared with healthy controls and resulted in a reduced relapse rate, a superior overall survival and resulted more often in the low risk group compared with IL-10 low producer haplotypes. By analysing immunosuppressive IL-6, it was demonstrated, that the genotype C/C is significantly more frequent in ALL-patients in comparison to healthy patients. Interestingly, with regard to IL-6 as well as to TNF-α genotypes a change in the genotype from initial diagnosis to remission was found in some patients, which may indicate a blast specific immune-escape mechanism. Moreover, the immune-modulatory cytokine TGF-β1 has an influence on risk group and relapse rate. Patients with a C/C in Codon 10 suffered more often from relapses than patients with G/C or G/G. TGF-β1 high producer haplotypes were correlated with a high initial blast-count (Codon 25 G/G) and were elevated in high-risk ALL-patients (Codon 10 T/T). For the TH1 cytokines IFN-γ and TNF-α no correlation between frequencies, risk group, type of leukaemia, re-lapse rate or overall survival could be found. Even though the mechanisms by which the cytokine polymorphisms influence the outcome of paediatric ALL remain to be determined, the data of the present study suggest an important contribution of cytokines to the pathogenesis of ALL and demonstrate their potential applicability in the clinical evaluation of prognosis in paediatric patients. Confirmatory studies correlating cytokine alleles with disease markers will support the concept of cytokine-mediated immune surveil-lance in humans as well as the importance of the genetic background of the patient for strong anti-tumour immunity and responses to therapy. These data can finally help to establish biomarkers for therapy stratification as well as immune-therapeutic tools in childhood ALL for a more risk-adapted therapy, in order to adapt the therapy intensity. However, for further studies an increase in sample size and a prospective multicentre evaluation would be desirable. Especially in hereditary diseases, single genes have only a small influence on the overall risk. That is why it is crucial to have a sufficiently high number of cases to detect even small effects. KW - Cytokine KW - Polymorphismus KW - Akute lymphatische Leukämie KW - Zytokingenpolymorphismus KW - akute lymphatische Leukämie bei Kindern KW - genetic cytokine polymorphism KW - acute lymphoblastic leukaemia KW - pediatric hematology oncology KW - Cancer biology KW - molecular biology of cytokines KW - Zytokin Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-133312 ER - TY - JOUR A1 - Bartelheim, Kerstin A1 - Nemes, Karolina A1 - Seeringer, Angela A1 - Kerl, Kornelius A1 - Buechner, Jochen A1 - Boos, Joachim A1 - Graf, Norbert A1 - Dürken, Matthias A1 - Gerss, Joachim A1 - Hasselblatt, Martin A1 - Kortmann, Rolf-Dieter A1 - Teichert von Luettichau, Irene A1 - Nagel, Inga A1 - Nygaard, Randi A1 - Oyen, Florian A1 - Quiroga, Eduardo A1 - Schlegel, Paul-Gerhardt A1 - Schmid, Irene A1 - Schneppenheim, Reinhard A1 - Siebert, Reiner A1 - Solano-Paez, Palma A1 - Timmermann, Beate A1 - Warmuth-Metz, Monika A1 - Frühwald, Michael Christoph T1 - Improved 6-year overall survival in AT/RT - results of the registry study Rhabdoid 2007 JF - Cancer Medicine N2 - Atypical teratoid rhabdoid tumors (AT/RT) are characterized by mutations and subsequent inactivation of SMARCB1 (INI1, hSNF5), a predilection for very young children and an unfavorable outcome. The European Registry for rhabdoid tumors (EU‐RHAB) was established to generate a common European database and to establish a standardized treatment regimen as the basis for phase I/II trials. Thus, genetic analyses, neuropathologic and radiologic diagnoses, and a consensus treatment regimen were prospectively evaluated. From 2005 to 2009, 31 patients with AT/RT from four countries were recruited into the registry study Rhabdoid 2007 and treated with systemic and intraventricular chemotherapy. Eight patients received high‐dose chemotherapy, 23 radiotherapy, and 17 maintenance therapy. Reference evaluations were performed in 64% (genetic analyses, FISH, MLPA, sequencing) up to 97% (neuropathology, INI1 stain). Germ‐line mutations (GLM) were detected in 6/21 patients. Prolonged overall survival was associated with age above 3 years, radiotherapy and achievement of a complete remission. 6‐year overall and event‐free survival rates were 46% (±0.10) and 45% (±0.09), respectively. Serious adverse events and one treatment‐related death due to insufficiency of a ventriculo peritoneal shunt (VP‐shunt) and consecutive herniation were noted. Acquisition of standardized data including reference diagnosis and a standard treatment schedule improved data quality along with a survival benefit. Treatment was feasible with significant but manageable toxicity. Although our analysis is biased due to heterogeneous adherence to therapy, EU‐RHAB provides the best available basis for phase I/II clinical trials. KW - AT/RT KW - EU‐RHAB Registry KW - pediatric brain tumor KW - Rhabdoid 2007 Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-164799 VL - 5 IS - 8 ER - TY - JOUR A1 - Stein, Roland Gregor A1 - Wollschläger, Daniel A1 - Kreienberg, Rolf A1 - Janni, Wolfgang A1 - Wischnewsky, Manfred A1 - Diessner, Joachim A1 - Stüber, Tanja A1 - Bartmann, Catharina A1 - Krockenberger, Mathias A1 - Wischhusen, Jörg A1 - Wöckel, Achim A1 - Blettner, Maria A1 - Schwentner, Lukas T1 - The impact of breast cancer biological subtyping on tumor size assessment by ultrasound and mammography - a retrospective multicenter cohort study of 6543 primary breast cancer patients JF - BMC Cancer N2 - Background Mammography and ultrasound are the gold standard imaging techniques for preoperative assessment and for monitoring the efficacy of neoadjuvant chemotherapy in breast cancer. Maximum accuracy in predicting pathological tumor size non-invasively is critical for individualized therapy and surgical planning. We therefore aimed to assess the accuracy of tumor size measurement by ultrasound and mammography in a multicentered health services research study. Methods We retrospectively analyzed data from 6543 patients with unifocal, unilateral primary breast cancer. The maximum tumor diameter was measured by ultrasound and/or mammographic imaging. All measurements were compared to final tumor diameter determined by postoperative histopathological examination. We compared the precision of each imaging method across different patient subgroups as well as the method-specific accuracy in each patient subgroup. Results Overall, the correlation with histology was 0.61 for mammography and 0.60 for ultrasound. Both correlations were higher in pT2 cancers than in pT1 and pT3. Ultrasound as well as mammography revealed a significantly higher correlation with histology in invasive ductal compared to lobular cancers (p < 0.01). For invasive lobular cancers, the mammography showed better correlation with histology than ultrasound (p = 0.01), whereas there was no such advantage for invasive ductal cancers. Ultrasound was significantly superior for HR negative cancers (p < 0.001). HER2/neu positive cancers were also more precisely assessed by ultrasound (p < 0.001). The size of HER2/neu negative cancers could be more accurately predicted by mammography (p < 0.001). Conclusion This multicentered health services research approach demonstrates that predicting tumor size by mammography and ultrasound provides accurate results. Biological tumor features do, however, affect the diagnostic precision. KW - histopathology KW - breast cancer KW - ultrasound KW - mammography KW - tumor size Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-161050 VL - 16 IS - 549 ER - TY - JOUR A1 - Diessner, Joachim A1 - Wischnewsky, Manfred A1 - Stüber, Tanja A1 - Stein, Roland A1 - Krockenberger, Mathias A1 - Häusler, Sebastian A1 - Janni, Wolfgang A1 - Kreienberg, Rolf A1 - Blettner, Maria A1 - Schwentner, Lukas A1 - Wöckel, Achim A1 - Bartmann, Catharina T1 - Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer JF - BMC Cancer N2 - Background The development of metastases is a negative prognostic parameter for the clinical outcome of breast cancer. Bone constitutes the first site of distant metastases for many affected women. The purpose of this retrospective multicentre study was to evaluate if and how different variables such as primary tumour stage, biological and histological subtype, age at primary diagnosis, tumour size, the number of affected lymph nodes as well as grading influence the development of bone-only metastases. Methods This retrospective German multicentre study is based on the BRENDA collective and included 9625 patients with primary breast cancer recruited from 1992 to 2008. In this analysis, we investigated a subgroup of 226 patients with bone-only metastases. Association between bone-only relapse and clinico-pathological risk factors was assessed in multivariate models using the tree-building algorithms “exhausted CHAID (Chi-square Automatic Interaction Detectors)” and CART(Classification and Regression Tree), as well as radial basis function networks (RBF-net), feedforward multilayer perceptron networks (MLP) and logistic regression. Results Multivariate analysis demonstrated that breast cancer subtypes have the strongest influence on the development of bone-only metastases (χ2 = 28). 29.9 % of patients with luminal A or luminal B (ABC-patients) and 11.4 % with triple negative BC (TNBC) or HER2-overexpressing tumours had bone-only metastases (p < 0.001). Five different mathematical models confirmed this correlation. The second important risk factor is the age at primary diagnosis. Moreover, BC subcategories influence the overall survival from date of metastatic disease of patients with bone-only metastases. Patients with bone-only metastases and TNBC (p < 0.001; HR = 7.47 (95 % CI: 3.52–15.87) or HER2 overexpressing BC (p = 0.007; HR = 3.04 (95 % CI: 1.36–6.80) have the worst outcome compared to patients with luminal A or luminal B tumours and bone-only metastases. Conclusion The bottom line of different mathematical models is the prior importance of subcategories of breast cancer and the age at primary diagnosis for the appearance of osseous metastases. The primary tumour stage, histological subtype, tumour size, the number of affected lymph nodes, grading and NPI seem to have only a minor influence on the development of bone-only metastases. KW - BRENDA KW - breast cancer KW - bone metastases KW - skeleton KW - breast cancer subtypes Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-161173 VL - 16 IS - 307 ER - TY - JOUR A1 - Drozd, Valentina M. A1 - Saenko, Vladimir A. A1 - Brenner, Alina V. A1 - Drozdovitch, Vladimir A1 - Pashkevich, Vasilii I. A1 - Kudelsky, Anatoliy V. A1 - Demidchik, Yuri E. A1 - Branovan, Igor A1 - Shiglik, Nikolay T1 - Major Factors Affecting Incidence of Childhood Thyroid Cancer in Belarus after the Chernobyl Accident: Do Nitrates in Drinking Water Play a Role? JF - PLoS One N2 - One of the major health consequences of the Chernobyl Nuclear Power Plant accident in 1986 was a dramatic increase in incidence of thyroid cancer among those who were aged less than 18 years at the time of the accident. This increase has been directly linked in several analytic epidemiological studies to iodine-131 (I-131) thyroid doses received from the accident. However, there remains limited understanding of factors that modify the I-131-related risk. Focusing on post-Chernobyl pediatric thyroid cancer in Belarus, we reviewed evidence of the effects of radiation, thyroid screening, and iodine deficiency on regional differences in incidence rates of thyroid cancer. We also reviewed current evidence on content of nitrate in groundwater and thyroid cancer risk drawing attention to high levels of nitrates in open well water in several contaminated regions of Belarus, i.e. Gomel and Brest, related to the usage of nitrogen fertilizers. In this hypothesis generating study, based on ecological data and biological plausibility, we suggest that nitrate pollution may modify the radiation-related risk of thyroid cancer contributing to regional differences in rates of pediatric thyroid cancer in Belarus. Analytic epidemiological studies designed to evaluate joint effect of nitrate content in groundwater and radiation present a promising avenue of research and may provide useful insights into etiology of thyroid cancer. KW - analysis KW - areas KW - power-station accident KW - iodine nutrition KW - skin hemagioma KW - pooled KW - risk KW - children KW - radiation KW - exposure KW - radiotherapy Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-141863 VL - 10 IS - 9 ER - TY - THES A1 - Ströbele, Hannah T1 - Neuropsychologische Diagnostik bei sehr und extrem Frühgeborenen im Alter von sechs bis acht Jahren – eine Pilotstudie mit der WUEP-KD (Würzburger Psychologische Kurz-Diagnostik) T1 - Neuropsychological assessment of very and extreme preterms at the age of six to eight years – a pilot study with the WUEP-KD N2 - Die gesetzlich vorgeschriebene Nachsorge von Frühgeborenen in Deutschland beschränkt sich nach den Vorgaben des G-BA momentan auf eine Entwicklungstestung mit den Bayley Scales of Infant Development im Alter von zwei Jahren. Entwicklungsuntersuchungen zu einem späteren Zeitpunkt sind jedoch notwendig, da neurologische Folgen bzw. Auswirkungen dann besser beurteilt und gemessen werden können. Die WUEP-KD ist eine neuropsychologische Testbatterie, die auf der CHC-Theorie basiert und den Vorteil einer guten Normierung und Validierung für deutsche Kinder, sowie einer kurzen Durchführungszeit hat. Außerdem wurden bereits langjährig Erfahrungen in der Anwendung bei Kindern mit anderen neuropsychologischen Problemen gesammelt. Wir wendeten die WUEP-KD bei sechs bis acht Jahre alten Kindern an, die in den Jahren 2001 und 2002 in der Frauenklinik der Universität Würzburg mit einem Geburtsgewicht von unter 1500g zur Welt gekommen waren und in der Universitätskinderklinik Würzburg behandelt wurden. Weiterhin wurden zehn termingerecht geborene und gesunde Kinder im gleichen Alter untersucht. Es stellte sich heraus, dass die Frühgeborenen, die an unserer Studie teilgenommen hatten, signifikant besser bei den BSID-II im Alter von zwei Jahren abgeschnitten hatten als diejenigen, die wir leider nicht von einer Teilnahme überzeugen konnten. Tendenziell zeigte sich in unserer Studie bezüglich der zentralen mentalen Leistungsfähigkeit dennoch eine geringere Leistung bei geringerem Gestationsalter und bzw. oder geringerem Geburtsgewicht. Die Ergebnisse des Untertests CPM, welcher die fluide Intelligenz abbildet, waren signifikant unterschiedlich beim Gruppenvergleich der Geburtsgewichte sowie des Gestationsalters. Somit konnten wir mit unserer Methodik ebenso wie in anderen Studien einen Unterschied in der kognitiven Leistung zwischen den VLBW-Kindern und den ELBW-Kindern im Alter von sechs bis acht Jahren nachweisen. Beim Vergleich mit den Untersuchungen im Alter von zwei bis drei Jahren konnten wir weitgehend eine gleichbleibende Leistung nachweisen, die Ergebnisse der Bayley-Scales und der mentalen Gesamtleistung der WUEP-KD korrelierten signifikant. Um eine umfassende Diagnostik durchzuführen und weitere Intelligenzfaktoren nach der CHC-Theorie zu erfassen, werden in der WUEP-KD computerisierte Tests verwendet. Zur Messung der feinmotorischen Leistung wurde hierfür das Speed-Tapping verwendet, welches bisher nicht in der Untersuchung Frühgeborener angewandt wurde. Die feinmotorischen Fähigkeiten der Früh- und Reifgeborenen lagen durchschnittlich im Normbereich, jedoch hatten doppelt so viele Frühgeborene als Reifgeborene Defizite in der Feinmotorik. Insbesondere die ELBW-Kinder waren hiervon betroffen. Bei Betrachtung der Frühgeborenen konnte eine signifikante Korrelation zwischen dem Gestationsalter und der feinmotorischen Leistung nachgewiesen werden. Somit konnten wir nachweisen, dass ein geringeres Geburtsgewicht und Gestationsalter das Risiko erhöhen, feinmotorische Defizite im Schulalter nachweisen zu können – auch wenn keine höhergradigen intrakraniellen Blutungen im Neugeborenenalter aufgetreten waren und die kognitive Leistung zum Zeitpunkt der Untersuchung im Normbereich liegt. Die WUEP-KD kann zusätzlich im Bereich der motorischen Fähigkeiten Defizite aufdecken. Die Aufmerksamkeitsleistung, gemessen mit dem CPT, lag im Normbereich, dennoch waren wiederum vermehrt Defizite bei den ELBW-Kindern und den Kindern mit einem Gestationsalter unter 29 SSW zu beobachten. Um das Verhalten und die Lebensqualität der frühgeborenen Kinder einschätzen zu können, ließen wir die Eltern drei Fragebögen beantworten (CBCL, SDQ, KINDL-R). Hier konnten wir größtenteils keine signifikanten Unterschiede zwischen den Reif- und Frühgeborenen feststellen. Im Fragebogen zur Lebensqualität konnten bei den Frühgeborenen sogar signifikant bessere Ergebnisse in den Bereichen „Freunde“ und „Selbstwert“ nachgewiesen werden. Die WUEP-KD stellt aus unserer Sicht eine geeignete Methodik dar, um frühgeborene Kinder in ihrer weiteren Entwicklung nachzuuntersuchen – sie basiert auf der CHC-Theorie, dem Goldstandard der Intelligenzdiagnostik, hat eine kurze Durchführungsdauer, es besteht eine langjährige Anwendung und Erfahrung in der Durchführung bei Kindern mit neuropsychologischer Problematik und hat die nun nachgewiesene Fähigkeit kognitive und motorische Defizite bei frühgeborenen Kindern aufzudecken. Hierdurch können die betroffenen Kinder in ihren Fähigkeiten und Grenzen besser eingeschätzt und somit gezielt betreut werden. N2 - The WUEP-KD is a neuropsychological assessment battery, which is based on the CHC-theory and has the advantage of a good standardization and validation for German children as well as a short performance time. We examined 36 preterms with a birth weight below 1500g and ten full-term children at the ages of six to eight years. We could demonstrate a significant increase in cognitive and fine-motor performances with increasing birth weight and gestational age. Regarding the attention performance we could see more deficits in the ELBWI (extreme low birth weight infants, <1000g) and in the children with a gestational age below 29 weeks. In our opinion the WUEP-KD is a useful tool to examine the further development of preterm children. The test offers a good assessment of the abilities and limitations of preterm children at the early school-age and parents can be counseled accordingly. KW - Neuropsychologische Diagnostik KW - Frühgeburt KW - Nachuntersuchung KW - CHC-Theorie KW - WUEP-KD KW - Frühgeborene KW - ELBWI KW - VLBWI Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-123896 ER - TY - THES A1 - Streib, Rebekka T1 - Die Bedeutung einer Zweitmalignomentwicklung nach primärer Hirntumorerkrankung im Kindesalter T1 - Role of second malignant neoplasms after childhood brain tumours N2 - In der vorliegenden Arbeit wurden Patienten untersucht, die im Rahmen der Hirntumorstudien SKK 87, SKK 92, HIT 88, HIT 91, der Interimsstudie HIT 99 sowie HIT 2000 der HIT-Studienzentrale in Würzburg aufgrund eines Hirntumors im Kindesalter behandelt wurden und an einem Zweitmalignom erkrankten. Es erfolgte die genauere Betrachtung insbesondere im Hinblick auf Patienteneigenschaften, zeitliche Verläufe, Risikofaktoren, kumulative Zweitmalignomhäufigkeiten und die Prognose nach einer Zweiterkrankung. Bis zum 01.01.2008 waren 54 Patienten bekannt, die nach einem primären Hirntumor im Kindesalter ein Zweitmalignom entwickelten, davon waren 29 männlich und 25 weiblich, 11 hatten ein bekanntes Tumorprädispositionssyndrom. Als Zweitmalignomhistologie traten vor allem sekundäre Hirntumoren (17) und sekundäre hämatologische Neoplasien (13) auf. Dabei traten hämatologische Zweitneoplasien deutlich früher als sekundäre Hirntumoren auf (im Median 4.9 versus 8.9 Jahre). Das mittlere Erkrankungsalter bei Erst- und Zweitdiagnose war 6.4 bzw. 13.1 Jahre bei einem mittleren Follow-up aller Studienpatienten seit Erstdiagnose von 10.8 Jahren. Als Risikofaktoren einer Zweitmalignomentwicklung konnte ein junges Erkrankungsalter und das weibliche Geschlecht ermittelt werden. Die kumulative Inzidenz einer Zweitmalignomentwicklung nach Aalen-Johansen lag 5, 10 und 15 Jahre nach Primärerkrankung bei 0.6%, 2% und 5%. Die 5-Jahres-Überlebensrate für alle 54 Zweitmalignompatienten nach Zweittumordiagnose betrug 35%. Die Arbeit verdeutlicht, dass mit steigender Langzeitprognose nach kindlichen Hirntumorerkrankungen Spätfolgen der Therapie immer relevanter werden. Damit steigt die Bedeutung der engmaschigen Nachsorge zur frühzeitigen Erkennung und Quantifizierung dieser Spätfolgen. N2 - The following paper describes survivors of childhood brain tumours who were registered to the multicentre Infant Brain Tumour trials SKK 87, SKK 92, HIT 88, HIT 91, HIT 99 and HIT 2000 in Wurzburg. Until 01.01.2008 a total of 54 of these brain tumour survivors developed secondary malignant neoplasms. 29 were male, 25 female; 11 had syndromal diseases. 17 patients developed secondary brain tumours and 11 patients had secondary hematopoietic malignancies. Hematopoietic malignancies developed earlier than secondary brain tumours (4.9 versus 8.9 years). The average age of patients at primary and secondary diagnosis was 6.4 and 13.1 years. The average follow-up of all patients who were treated in the named trials was 10.8 years. Risk factors for second malignant neoplasms were young age and female gender. The cumulative incidences for second neoplasms were 0.6%, 2% and 5% at 5, 10 and 15 years. The five-year survival rate for patients after the diagnosis of a second malignant neoplasm was 35%. With improved prognosis after childhood brain tumours there is an increasing risk of long term effects of therapy. Long-term follow-up demonstrates a relatively high risk for secondary malignant neoplasms. KW - Zweittumor KW - Hirntumor KW - Kind KW - Spätschaden KW - Zweitmalignom KW - Primärer Hirntumor KW - Kindheit Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-124306 ER - TY - JOUR A1 - Eberhardt, Christiane S. A1 - Haas, Johannes-Peter A1 - Girschick, Hermann A1 - Schwarz, Tobias A1 - Morbach, Henner A1 - Rösen-Wolff, Angela A1 - Foell, Dirk A1 - Dannecker, Guenther A1 - Schepp, Carsten A1 - Ganser, Gerd A1 - Honke, Nora A1 - Eggermann, Thomas A1 - Müller-Berghaus, Jan A1 - Wagner, Norbert A1 - Ohl, Kim A1 - Tenbrock, Klaus T1 - No association of IL-12p40 pro1.1 polymorphism with juvenile idiopathic arthritis JF - Pediatric Rheumatology N2 - Background: IL-12p40 plays an important role in the activation of the T-cell lines like Th17 and Th1-cells. Theses cells are crucial in the pathogenesis of juvenile idiopathic arthritis. A polymorphism in its promoter region and the genotype IL12p40 pro1.1 leads to a higher production of IL-12p40. We studied whether there is a difference in the distribution of the genotype in patients with JIA and the healthy population. Methods: In 883 patients and 321 healthy controls the IL-12p40 promoter genotype was identified by ARMS-PCR. Results: There is no association of IL-12p40 pro polymorphism neither in patients with JIA compared to controls nor in subtypes of JIA compared to oligoarthritis. We found a non-significant tendency of a higher prevalence of the genotype pro1.1 in systemic arthritis (32.4 %) and in rheumatoid factor negative polyarthritis (30.5 %) and a lower pro1.1 genotype in persistent oligoarthritis (20.7 %) and in enthesitis-related arthritis (17 %). Likelihood of the occurrence of genotype IL12-p40 pro1.1 in patients with systemic arthritis (OR 1.722, CI 95 % 1.344-2.615, p 0.0129) and RF-negative polyarthritis (OR 1.576, CI 95 % 1.046-2.376, p 0.0367) compared to persistent oligoarthritis was significantly higher. This was also true for comparison of their homozygous genotypes IL-12p40 pro 1.1 and 2.2 in systemic arthritis (OR 1.779, CI 95 % 1.045-3.029, p 0.0338). However, in Bonferroni correction for multiple hypothesis this was not significant. Conclusion: A tendency of a higher prevalence of the genotype IL-12p40 pro1.1 in systemic arthritis and in rheumatoid factor negative polyarthritis was observed but not significant. Further investigations should be done to clarify the role IL-12p40 in the different subtypes of JIA. KW - polymorphism KW - cytokine KW - children KW - serum KW - IL12B KW - gene KW - cells KW - juvenile idiopathic arthritis KW - IL-12p40 KW - IL-12B KW - promoter Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-136281 VL - 13 IS - 61 ER - TY - JOUR A1 - Harter, Patrick N. A1 - Bernatz, Simon A1 - Scholz, Alexander A1 - Zeiner, Pia S. A1 - Zinke, Jenny A1 - Kiyose, Makoto A1 - Blasel, Stella A1 - Beschorner, Rudi A1 - Senft, Christian A1 - Bender, Benjamin A1 - Ronellenfitsch, Michael W. A1 - Wikman, Harriet A1 - Glatzel, Markus A1 - Meinhardt, Matthias A1 - Juratli, Tareq A. A1 - Steinbach, Joachim P. A1 - Plate, Karl H. A1 - Wischhusen, Jörg A1 - Weide, Benjamin A1 - Mittelbronn, Michel T1 - Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases JF - Oncotarget N2 - The activation of immune cells by targeting checkpoint inhibitors showed promising results with increased patient survival in distinct primary cancers. Since only limited data exist for human brain metastases, we aimed at characterizing tumor infiltrating lymphocytes (TILs) and expression of immune checkpoints in the respective tumors. Two brain metastases cohorts, a mixed entity cohort (n = 252) and a breast carcinoma validation cohort (n = 96) were analyzed for CD3+, CD8+, FOXP3+, PD-1+ lymphocytes and PD-L1+ tumor cells by immunohistochemistry. Analyses for association with clinico-epidemiological and neuroradiological parameters such as patient survival or tumor size were performed. TILs infiltrated brain metastases in three different patterns (stromal, peritumoral, diffuse). While carcinomas often show a strong stromal infiltration, TILs in melanomas often diffusely infiltrate the tumors. Highest levels of CD3+ and CD8+ lymphocytes were seen in renal cell carcinomas (RCC) and strongest PD-1 levels on RCCs and melanomas. High amounts of TILs, high ratios of PD-1+/CD8+ cells and high levels of PD-L1 were negatively correlated with brain metastases size, indicating that in smaller brain metastases CD8+ immune response might get blocked. PD-L1 expression strongly correlated with TILs and FOXP3 expression. No significant association of patient survival with TILs was observed, while high levels of PD-L1 showed a strong trend towards better survival in melanoma brain metastases (Log-Rank p = 0.0537). In summary, melanomas and RCCs seem to be the most immunogenic entities. Differences in immunotherapeutic response between tumor entities regarding brain metastases might be attributable to this finding and need further investigation in larger patient cohorts. KW - B7-H1 KW - PD-L1 KW - immunoresistance KW - immunosurveillance KW - safety KW - survival KW - expression KW - melanoma KW - breast cancer KW - PC-1 blockade KW - cell lung cancer KW - tumor-infiltrating lymphocytes KW - brain metastases KW - PD-1 Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-137107 VL - 6 IS - 38 SP - 40836 EP - 40849 ER - TY - THES A1 - Richard, Annika T1 - Systematic Review of Measles, Mumps and Rubella Vaccination Programs in Selected European Countries and the Influence of Migration Movements T1 - Systematischer Review der Impfstrategien für Masern, Mumps und Röteln in ausgewählten europäischen Ländern und die Auswirkungen von Migrationsbewegungen N2 - Masern, Mumps und Röteln sind virale Infektionskrankheiten, die schwere und verheerenden Komplikationen bei den erkrankten Personen verursachen können. Die weltweite Krankheitslast dieser Infektionskrankheiten ist hoch und könnte durch erfolgreiche Impfstrategien merkenswert reduziert werden. Die WHO hat daher das Ziel der globalen Eliminierung von Masern und Röteln sowie der Kontrolle der oft simultan geimpften Mumps Erkrankung gesetzt. Im Jahr 2010 einigten sich die WHO-Mitgliedstaaten der europäischen Region, gezielte Strategien zu verfolgen, um Masern und Röteln bis Ende des Jahres 2015 in Europa zu eliminieren. Analysen bezüglich des aktuellen Fortschrittes werden daher zunehmend relevanter. Als Teil dieser systematischen Literaturrecherche wurden die Immunisierungsstrategien, Impfraten und Krankheitsinzidenzen von elf europäischen Ländern untersucht und ihre Fortschritte im Hinblick auf die Krankheitseliminierung bewertet. Eine erfolgreiche Prävention der endemischen Übertragung von Masern, Mumps oder Röteln Viren konnte in mehreren Ländern erreicht werden, darunter Schweden, Kroatien, Griechenland und Spanien. Den Ländern Österreich, Frankreich, Deutschland, Italien, Polen, Türkei und dem Vereinigten Königreich von Großbritannien und Nordirland ist es trotz verbesserter Immunisierungsraten bisher nicht gelungen, die Eliminierungsziele zu erreichen. In der Türkei, Italien und Polen, kam es in den letzten Jahren zu starken Anstiegen der Fallzahlen, welche die Masern, Mumps und Röteln Kontrolle in Europa deutlich erschweren und das zeitnahe Erreichen der Eliminationsziele gefährden. Unzureichend immunisierte Bevölkerungsgruppen, die zu einer Aufrechterhaltung der Infektionserkrankungen im europäischen Raum beitragen können, wurden identifiziert. Dazu zählen Säuglinge und Kleinkinder, Jugendliche und junge Erwachsene, Männer, kürzlich eingewanderte Personen und Flüchtlinge, sowie reisende ethnischer Minderheiten. Die Gründe für das erhöhte Risiko einer Masern, Mumps oder Röteln Infektion unter diesen Personengruppen sind vielfältig und ein Ergebnis von verschiedenen historischen und aktuellen Impfstrategien, kulturellen, politischen und religiösen Unterschieden, sowie persönlichem Glauben und Ansichten. Das Reisen und die Migration von infizierten Personen nach und zwischen den verschiedenen europäischen Ländern spielt auch eine wesentliche Rolle bei der kontinuierlichen Übertragung der Erkrankungen in Europa. Nur durch eine ausreichend hohe Immunität der Bevölkerung kann das Auftreten von größeren Ausbrüchen trotz der Einfuhr viraler Erreger verhindert werden. Bestrebungen sollte daher die Immunisierung aller impffähigen Personen umfassen, sowie die Erweiterung spezifischer Impfstrategien für unzureichend immunisierte Bevölkerungsgruppen, die nur schwer durch Routineimpfungen zu erreichen sind. Europäische Länder, in denen die WHO Eliminierungsziele bisher nicht erreicht wurden, könnten möglicherweise von alternativen Impfstrategien profitieren. Ein einheitlicher, europaweiter MMR-Impfplan basierend auf den erfolgreichen Immunisierungsverfahren der Länder, die Masern, Mumps und Röteln erfolgreich bekämpft haben, stellt ein wirksames Instrument zur Verbesserung der allgemeinen Bevölkerungsimmunität und Kontrolle der drei Infektionskrankheiten dar. Ein Entwurf solch eines Impfplanes wurde im Rahmen dieser Dissertation erstellt und enthält Strategien für das Erreichen ungeschützter Bevölkerungsgruppen, unabhängig von Alter, Geschlecht oder Migrationshintergrund. Die Umsetzung einheitlicher Impfempfehlungen bringt mehrere Herausforderungen mit sich. Die vielen Vorteile im Hinblick auf die verbesserte Immunisierung, Überwachung und Bekämpfung der Erkrankungen lassen die Aufwände jedoch als berechtigt erscheinen. Die endemische Eliminierung von Masern, Mumps und Röteln Viren innerhalb der europäischen Region ist durchaus erzielbar. Die aktuelle epidemiologische Situation deutet jedoch darauf hin, dass das Ziel nicht bis zum Ende des Jahres 2015 erreicht wird, sondern weitere Bestrebungen auf internationaler Ebene notwendig sind, um eine wirksame Krankheitsbekämpfung in der näheren Zukunft zu erreichen. Durch nationale und internationale Verbesserungen der Immunisierungsstrategien und gezielten Impfkampagnen sowie Erkrankungs-Meldesystemen und laborchemischen Erregerbestätigungen kann eine weitgefächerte Bevölkerungsimmunität erzielt und Krankheitseliminierung unter adäquatem Monitoring des Fortschritts im gesamten europäischen Raum erreicht werden. N2 - Measles, mumps and rubella are viral infectious diseases that may cause severe and devastating complications among affected individuals. The disease burden of all three diseases is high, but could be reduced entirely through successful vaccination strategies. As such, the WHO has established the goal of globally eliminating measles and rubella and concomitantly controlling the frequently co-vaccinated mumps. In 2010, the WHO European Region member states agreed to strengthen efforts to eliminate measles and rubella from Europe by the end of 2015. As this date draws closer, progress analyses become increasingly relevant. In this systematic literature review, the immunization strategies, vaccination coverages and disease incidences of eleven European nations were assessed and their progress towards disease elimination evaluated. Successful prevention of the endemic transmission of measles, mumps, or rubella could be achieved in several nations, including Sweden, Croatia, Greece and Spain. Austria, France, Germany, Italy, Poland, Turkey and the United Kingdom of Great Britain and Northern Ireland, though having improved their overall immunization rates, have not yet been able to reach the elimination goals. In Turkey, Italy and Poland, sharp increases in case numbers during recent years are potentially threatening the successful measles, mumps and rubella control in Europe. Pockets of susceptible population groups that may contribute to the perpetuation of the diseases have been identified. They include infants and young children, adolescents and young adults, adolescent and adult males, recent immigrants and refugees,and traveling ethnic minority groups. Reasons for the increased risk of infection among these groups are manifold and a result of various historic and current vaccination practices, cultural, political and religious differences, as well as individual believes and concerns. Travel and migration of infected individuals to and between the various European nations also play an essential role in the continual transmission of measles, mumps and rubella in Europe. Only an adequate population-wide immunity can prevent the occurrence of major outbreaks due to viral importation. Efforts should therefore be made to immunize all population members able to receive vaccinations and to offer additional immunization opportunities to those susceptible population subgroups that are difficult to reach through routine vaccination programs. In countries struggling to meet the WHO elimination goals, alternative immunization practices may be necessary. A uniform, European-wide MMR vaccination schedule based on the successful immunization methods of countries that have eliminated measles, mumps and rubella may be an effective tool for improving the overall population-wide immunity and controlling the three diseases. A model for such a schedule was created and includes strategies for reaching population members regardless of age, gender or migratory background. The implementation of uniform immunization recommendations is challenging, but the advantages in terms of improved vaccination, surveillance and disease control methods may be worth at least considering such a strategy in Europe. Measles, mumps and rubella elimination may be attainable in the WHO European Region. The current epidemiological situation suggests that the goal is unlikely to be reached by the end of 2015, but through continued international efforts and collaboration, effective disease control could be achieved in the near future. In the meantime, improvements in immunization strategies, vaccination coverages, supplementary campaigns as well as disease notification systems and confirmations should be made on a national and international level, so that an adequate population-wide immunity can be established and the disease elimination progresses effectively monitored within the entire European region. KW - Masern KW - Mumps KW - Röteln KW - Impfung KW - systematic review KW - migration KW - Impfplan KW - vaccination program Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-138033 ER - TY - JOUR A1 - Neuhaus, Winfried A1 - Schlundt, Marian A1 - Fehrholz, Markus A1 - Ehrke, Alexander A1 - Kunzmann, Steffen A1 - Liebner, Stefan A1 - Speer, Christian P. A1 - Förster, Carola Y. T1 - Multiple antenatal dexamethasone treatment alters brain vessel differentiation in newborn mouse pups JF - PLoS ONE N2 - Antenatal steroid treatment decreases morbidity and mortality in premature infants through the maturation of lung tissue, which enables sufficient breathing performance. However, clinical and animal studies have shown that repeated doses of glucocorticoids such as dexamethasone and betamethasone lead to long-term adverse effects on brain development. Therefore, we established a mouse model for antenatal dexamethasone treatment to investigate the effects of dexamethasone on brain vessel differentiation towards the blood-brain barrier (BBB) phenotype, focusing on molecular marker analysis. The major findings were that in total brains on postnatal day (PN) 4 triple antenatal dexamethasone treatment significantly downregulated the tight junction protein claudin-5, the endothelial marker Pecam-1/CD31, the glucocorticoid receptor, the NR1 subunit of the N-methyl-D-aspartate receptor, and Abc transporters (Abcb1a, Abcg2 Abcc4). Less pronounced effects were found after single antenatal dexamethasone treatment and in PN10 samples. Comparisons of total brain samples with isolated brain endothelial cells together with the stainings for Pecam-1/CD31 and claudin-5 led to the assumption that the morphology of brain vessels is affected by antenatal dexamethasone treatment at PN4. On the mRNA level markers for angiogenesis, the sonic hedgehog and the Wnt pathway were downregulated in PN4 samples, suggesting fundamental changes in brain vascularization and/or differentiation. In conclusion, we provided a first comprehensive molecular basis for the adverse effects of multiple antenatal dexamethasone treatment on brain vessel differentiation. KW - preterm birth KW - fetal lung KW - corticosteroids KW - glucocorticoids KW - exposure KW - endothelial cells KW - in vitro KW - barrier KW - expression KW - rat Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-148268 VL - 10 IS - 8 ER - TY - JOUR A1 - Girschick, Hermann A1 - Wolf, Christine A1 - Morbach, Henner A1 - Hertzberg, Christoph A1 - Lee-Kirsch, Min Ae T1 - Severe immune dysregulation with neurological impairment and minor bone changes in a child with spondyloenchondrodysplasia due to two novel mutations in the ACP5 gene JF - Pediatric Rheumatology N2 - Spondyloenchondrodysplasia (SPENCD) is a rare skeletal dysplasia, characterized by metaphyseal lesions, neurological impairment and immune dysregulation associated with lupus-like features. SPENCD is caused by biallelic mutations in the ACP5 gene encoding tartrate-resistant phosphatase. We report on a child, who presented with spasticity, multisystem inflammation, autoimmunity and immunodeficiency with minimal metaphyseal changes due to compound heterozygosity for two novel ACP5 mutations. These findings extend the phenotypic spectrum of SPENCD and indicate that ACP5 mutations can cause severe immune dysregulation and neurological impairment even in the absence of metaphyseal dysplasia. KW - resistant acid phosphatase KW - expression KW - systemic lupus erythematosus KW - cerebral calcification KW - deficiency KW - autoimmunity KW - dysplasia KW - trap KW - spondyloenchondrodysplasia KW - ACP5 KW - immunodeficiency KW - type I interferonopathy Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-149990 VL - 13 IS - 37 ER -